Pfizer licenses small molecule drug delivery technology from Serina
Pharmaceutical Technology
NOVEMBER 20, 2023
Serina Therapeutics’ polymer aims to overcome certain limitations of the commonly used polyethylene glycol for drug delivery.
Biogen licenses subcutaneous drug delivery system for neurological drugs
Outsourcing Pharma
JANUARY 12, 2023
Biogen partners with Alcyone to gain access to ThecaFlex, which is able to deliver therapies into the intrathecal space.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Halozyme, doubling down on a licensing strategy, buys a drug delivery biotech for nearly $1B
Bio Pharma Dive
APRIL 13, 2022
Antares Pharma's auto-injector technology is of particular interest to Halozyme, which believes that the various markets to which it could be applied represent billions of dollars in potential sales.
Drug Delivery 
144
144 
Argenx widens its Halozyme Therapeutics-partnered net with 4 new targets in $30M license expansion
Fierce Pharma
OCTOBER 3, 2024
With a recently acquired FDA nod for its Halozyme Therapeutics-partnered Vyvgat Hytrulo, argenx is looking to take Halozyme’s delivery tech to new heights through a $30 million licensing deal that | The company's collaboration with drug delivery partner Halozyme Therapeutics now totals six targets and could result in milestone payments of up to (..)
Licensing 75
75 
Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio tech
pharmaphorum
JANUARY 12, 2021
ImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from UK biotech iosBio. The post Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio tech appeared first on.
Licensing 119
119 
Vect-Horus lands licensing pact with Novo Nordisk to improve drug delivery
BioPharma Reporter
OCTOBER 31, 2023
The French biotech company Vect-Horus has licensed its technology to the Danish big pharma Novo Nordisk to deliver drug cargoes to undisclosed disease targets in three programs.
Licensing 59
59 
Suono Bio, Inc. Announces Exclusive Patent License with MIT for Portfolio of Granted IP Covering Formulation-Independent Drug Delivery
BioTech 365
DECEMBER 1, 2021
Announces Exclusive Patent License with MIT for Portfolio of Granted IP Covering Formulation-Independent Drug Delivery Suono Bio, Inc. Announces Exclusive Patent License with MIT for Portfolio of Granted IP Covering Formulation-Independent Drug Delivery FOXBOROUGH, Mass.–(BUSINESS Suono Bio, Inc.
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV
BioTech 365
JUNE 22, 2021
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to … Continue reading →
Satsuma submits new drug application for STS101 to the US FDA
Pharmaceutical Technology
APRIL 17, 2023
US-based development-stage biopharmaceutical firm Satsuma Pharmaceuticals is developing STS101, a unique nasal powder formulation of the anti-migraine drug dihydroergotamine mesylate, for the treatment of acute migraine. SNBL has also signed a definitive agreement to acquire Satsuma Pharmaceuticals. in cash per share.
Drugs 147
147 
Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and Age-related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery Technology
BioTech 365
AUGUST 19, 2021
Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and Age-related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery Technology Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and Age-related Macular Degeneration; Secures (..)
AstraZeneca buys cell therapy biotech for up to $1bn
pharmaphorum
MARCH 18, 2025
AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen.
In-Vivo 66
66 
IXCHIQ Chikungunya Vaccine Trial Shows Sustained Immune Response in Adolescents
XTalks
JANUARY 22, 2025
IXCHIQ is the only licensed chikungunya vaccine in the US for adults aged 18 and older at increased risk of exposure to the virus. This includes post-marketing studies, label extensions for younger populations and a licensing agreement with the Serum Institute of India to supply the vaccine in Asia at affordable prices.
Medincell, AbbVie link up in long-acting injectable development pact worth up to $1.9B
Fierce Pharma
APRIL 17, 2024
After proving the merits of its drug delivery platform last year with the approval of Teva’s long-acting schizophrenia drug Uzedy, France’s Medincell has hooked another big-name partner. Medincell and AbbVie inked a development and licensing pact to create up to six long-acting injectables, Medincell said Wednesday.
Development 81
81 
Evotec, Chinook Teams Up for CKD Therapy; HitGen & UPPTHERA in Drug Delivery Research; Artiva’s $120 M Coup of NK Cell Therapy; Junshi & AZ with Toripalimab in China
Delveinsight
MARCH 2, 2021
HitGen & UPPTHERA Collaborate for Drug Delivery Research. HitGen has entered into a collaboration for drug discovery research with UPPTHERA to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase. Junshi & AstraZeneca To Commercialize Toripalimab in China.
Crescita Announces Licensing Agreement for Pliaglis; in China
The Pharma Data
NOVEMBER 4, 2020
Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8
Licensing 40
40 
Rising Need of Autoinjectors
Roots Analysis
FEBRUARY 22, 2022
Autoinjector As Emerging Drug Delivery Device. The field is presently witnessing several innovations, such as LED / LCD-based visualization, Bluetooth connectivity, dosage recording, safety lock, visual / audible drug delivery confirmation notifications, and automatic drug reconstitution. Concluding Remarks.
Restructuring announced at ReNeuron as another CEO resigns
pharmaphorum
JANUARY 3, 2023
The change at the top comes as ReNeuron is in the throes of a pivot in its business after years of stuttering progress with stem cell programmes and a perennial shortage of operating cash, with the company announcing in July it would concentrate efforts on a proprietary exosome drug delivery platform.
FOSTAIR inhaler – TOP questions & ANSWERS
Druggist
NOVEMBER 19, 2020
Initial license for Fostair included only maintenance therapy in adults over 18 years of age. In 2012 licensed was updated and since then Fostair can also be used as a reliever , taken accordingly to asthma symptoms. A spacer may offer drug delivery benefits in a wider patient group. Able Spacer®. Space Chamber Plus.
Pharmacy 69
69 
TLC Announces the Appointment of Thomas H. Bliss, Jr., MBA, as Chief Business Officer
The Pharma Data
OCTOBER 20, 2020
We look forward to successful commercialization and licensing of TLC’s programs across the globe under Mr. Bliss’s leadership, as well as to creating benefit and bringing value for all of TLC’s stakeholders.”. Earlier in his career, he ran business-development functions at Amgen and Baxter.
Licensing 40
40 
Update: FDA clears first generic of AZ’s blockbuster Symbicort
pharmaphorum
MARCH 16, 2022
Viatris’ generic of Symbicort (budesonide and formoterol fumarate dihydrate) – developed by Viatris in collaboration with 3M spin-off company Kindeva Drug Delivery and called Breyna – has been cleared for the same indications as the brand, namely maintenance treatment for asthma and chronic obstructive pulmonary disease (COPD).
FDA Approval 59
59 
BetterLife Closes Acquisition of Second Generation Psychedelic Assets of Transcend Biodynamics LLC
The Pharma Data
DECEMBER 20, 2020
With this acquisition we are expanding our product pipeline to include psychedelic therapeutics, incorporating elements of our IP around drug delivery technology in which we already have prototypes developed, which we believe will propel us towards clinical studies relatively quickly. Ahmad Doroudian, CEO of BetterLife.
Injecting Innovation: The Rising Trend of Autoinjectors in Modern Medicine
Roots Analysis
JUNE 6, 2024
In July 2023, Crossject partnered with AFT Pharmaceuticals for licensing, distribution and promotion of ZENEO Midazolam for patients with epileptic seizures in Australia and New Zealand. The autoinjectors market is poised to mirror this growth pattern as more individuals transition from traditional to user-centric drug delivery options.
Medicine 40
40 
Novartis presents new findings at ERS reinforcing the efficacy of.
The Pharma Data
SEPTEMBER 2, 2021
GLY certain use and formulation intellectual property were exclusively licensed to Novartis in April 2005 by Sosei Heptares and Vectura. MF is exclusively licensed to Novartis from a subsidiary of Merck & Co., Mometasone furoate is exclusively licensed to Novartis from a subsidiary of Merck & Co., g) formulations.
Licensing 52
52 
BetterLife Pharma Strengthens Board of Directors
The Pharma Data
DECEMBER 28, 2020
is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. About BetterLife Pharma Inc. BetterLife Pharma Inc.
Containment 52
52 
Midatech Pharma PLC Announces Business Update
The Pharma Data
JANUARY 25, 2021
Further to the update outlined in the Company’s results for the year ended 31 December 2019, Secura Bio, Inc. (“Secura Bio”), the licensor of panobinostat, the API component of MTX110, has twice declined an invitation to withdraw its purported termination of the license.
Containment 52
52 
Vivera Pharmaceuticals Announces $440 Million in Backing by JR Dallas Wealth Management
The Pharma Data
NOVEMBER 25, 2020
In addition to its pharmaceutical, medical device, advanced diagnostics, medical supply, medical technologies, neurosciences, and health and human service divisions, the Company has global exclusivity to license the patented and patent-pending TABMELT ® sublingual drug-delivery system for the pharmaceutical use of therapeutic compounds.
FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD)
The Pharma Data
JUNE 26, 2021
Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD). Roche (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S.
EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics
The Pharma Data
JANUARY 3, 2021
The Company’s pipeline leverages its proprietary bioerodible Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration.
Production 52
52 
BetterLife Confirms Non-controlled Status of 2-bromo-LSD with Health Canada
The Pharma Data
JANUARY 18, 2021
Utilizing drug delivery platform technologies, BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV).
Containment 40
40 
BetterLife’s Recent Acquisition: Taking LSD from Experimental to a Major Therapeutic Application
The Pharma Data
DECEMBER 14, 2020
is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. About BetterLife Pharma Inc. BetterLife Pharma Inc. For further information please visit www.abetterlifephama.com. About Transcend Biodynamics.
BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies
The Pharma Data
JANUARY 27, 2021
Utilizing drug delivery platform technologies, BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus.
In-Vitro 52
52 
Ovation Science Secures Listing for DermSafe on Amazon.ca to Increase Direct to Canadian Consumer Purchases
The Pharma Data
OCTOBER 27, 2020
With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation’s management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas.
Sales 52
52 
MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea On 14th, MEDICOX, listed on KOSDAQ, signed an exclusive distribution contract with an oral drug delivery platform developer, ORAMED Pharmaceuticals on the oral insulin license. EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent ?-thalassemia EdiGene, Inc., a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs, announced it had completed the last patient dosing in Phase I clinical trial of ET-01, its investigational gene-editing hematopoietic stem cell therapy for transfusion dependent ?-thalassemia. Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022 Regulatory News: Lysogene announced that it will h
BioSpace
NOVEMBER 17, 2022
Editas Medicine is pausing its ocular gene therapy program after demonstrating a favorable safety profile and seeking a potential partner to develop EDIT-101, the company announced Thursday.
Gene Therapy 42
42 
Revolo Biotherapeutics’ Unique Approach to Developing Treatments for Autoimmune and Allergic Diseases
XTalks
JUNE 21, 2024
Dr. Bryan began his career at Schering-Plough, engaging in formulation and drug delivery. Bryan says he was particularly drawn to the early-stage data from Revolo Biotherapeutics’ ‘1104 and ‘1805 therapeutic assets, which showed promise in various therapeutic avenues.
Development 52
52 
argenx’s CIDP Commercial Highlights the Impact of New Treatments on Patient Lives
XTalks
MAY 30, 2024
Potential New CIDP Treatment: argenx’s Efgartigimod Alfa The US Food and Drug Administration (FDA) has accepted argenx’s supplemental Biologics License Application (sBLA) for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for priority review to treat CIDP.
FDA Approval 40
40 
Best Toenail Fungus Treatment Products
Druggist
OCTOBER 21, 2020
Additionally, oral antifungal tablets are not licensed for use in children. Overall, oral treatment with drugs cure toenail infections more quickly and effectively than topical treatments (Cochrane, 2017). Novel Drug Delivery Strategies for the Treatment of Onychomycosis. J Am Board Fam Med. 2011 Jan-Feb;24(1):69-74.
Production 98
98 TLC Provides Corporate Update at Investor Conference – Dec 18, 2020
The Pharma Data
DECEMBER 17, 2020
With experiences attained in licensing and business development functions from Amgen, Baxter and Johnson & Johnson, Mr. Bliss introduced himself in Mandarin Chinese. SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec.
FDA accepts application for Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)
The Pharma Data
MAY 15, 2023
Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Vabysmo® (faricimab) for the treatment of macular edema following retinal vein occlusion (RVO). 1,2 Vabysmo’s safety profile was consistent with previous trials. Review by other regulatory authorities is ongoing.
Antibody 40
40 
Subcutaneous Medications and Drug Delivery Systems
Roots Analysis
FEBRUARY 26, 2024
Several Technology Providers, with Proprietary Platforms, have Emerged as Key Enablers Several technology developers have licensed their platforms to other pharmaceutical companies for developing subcutaneous formulation of their approved / pipeline products.
Using analytics and bioassays to de-risk your mRNA LNP drug development programme
Pharmaceutical Technology
FEBRUARY 15, 2023
“At the small scale, manufacturing between 1 ml and 10 ml is typically not problematic , but it’s not straightforward to replicate processes and technologies once you want to produce tens of litres of formulations,” says Dr Crowe, who manages a team that develop novel analytical assays related to LNPs and nanomaterials for drug delivery.
Bioassay 130
130 
Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics
The Pharma Data
JUNE 7, 2023
LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery. Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver.
Gene Therapy 40
40 
Pharmacy Law and Licensing Highlights 2025
FDA Law Blog
FEBRUARY 2, 2025
By Sara M Keup In reviewing some new 2025 pharmacy rules/laws a couple interesting changes caught this bloggers attention: As of December 30, 2024, Missouri has rolled out new rules related to prescription drug delivery requirements. The California Board of Pharmacy updated many of the application forms and guidelines in late 2024.
Pharmacy 59
59 
Darzalex Faspro (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
The Pharma Data
JANUARY 15, 2021
and Genmab A/S entered into a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize daratumumab. Darzalex Faspro® is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE® drug delivery technology.
FDA Approval 52
52 
Leveraging a Drug Patent Portfolio for Success
Drug Patent Watch
DECEMBER 19, 2024
This includes novel drug delivery systems, extended-release formulations, or unique combinations of ingredients that enhance efficacy or reduce side effects. Methods of Treatment These patents protect specific ways of using a drug to treat particular conditions.
Drugs 92
92 
Let's personalize your content